

You're invited to join us for A LIVE CAPLYTA EDUCATIONAL PROGRAM

This is a promotional program sponsored by Intra-Cellular Therapies, Inc.

CAPLYTA
(lumateperone) capsules

Clinical Evidence Supporting the Use of CAPLYTA in Bipolar Depression

Boxed Warnings:

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.
- Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of CAPLYTA have not been established in pediatric patients.

Please see additional Important Safety Information on the following page.

Program details

Tuesday, January 16, 2024

6:30 PM CT

The West Table

1204 Broadway

Lubbock, TX 79401

Registration information

You can register by visiting

<https://www.itcpsychcenter.com/?code=ACVVYX>

or by scanning the QR code below.



Speaker information

Joel Holiner, MD

Dallas, TX

Sales specialist information

Shawon Harris

(325) 829-1882

sharris@itci-inc.com

For more information or to explore additional resources, please visit **ITCIPsychCenter.com**


Intra-Cellular Therapies Policies

- Attendance at venue-based speaker programs is limited to HCPs with prescribing authority and/or licensed professionals, such as MDs, PAs, NPs, Nurses (RNs, LPNs, APRNs), Social Workers, Psychologists, Pharmacists, Licensed Professional Counselors, and Medical Students. Non-HCP office staff, spouses, or other guests are not permitted.
- Attendees may not include employees of the speaker's own medical practice (same physical location) or staff of facilities for which the speaker is a medical director (whose job function it is to educate those within their supervisory authority).
- An individual must not attend a Speaker Program on the same topic more than 3 times in a 12-month period.
- Alcohol, including beer or wine, will not be served or permitted at this program.

About the Intra-Cellular Therapies Psych Center

The Intra-Cellular Therapies Psych Center was created to provide educational opportunities related to CAPLYTA for the treatment of adult patients with bipolar depression–bipolar I or II and schizophrenia. Healthcare professionals can utilize the Psych Center to register for educational CAPLYTA programs, access CAPLYTA resources, learn about patient support, watch expert-led videos, and more.

To request CAPLYTA samples or vouchers that can be sent directly to your patients, scan the QR code(s) below.



Samples



Vouchers

CAPLYTA® (lumateperone) is indicated in adults for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy and as adjunctive therapy with lithium or valproate.

Important Safety Information (continued)

Contraindications: CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA. Reactions have included pruritus, rash (e.g., allergic dermatitis, papular rash, and generalized rash), and urticaria.

Warnings & Precautions: Antipsychotic drugs have been reported to cause:

- **Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis**, including stroke and transient ischemic attack. See Boxed Warning on previous page.
- **Neuroleptic Malignant Syndrome**, which is a potentially fatal reaction. Signs and symptoms include hyperpyrexia, muscle rigidity, delirium, autonomic instability, elevated creatinine phosphokinase, myoglobinuria (and/or rhabdomyolysis), and acute renal failure. Manage with immediate discontinuation of CAPLYTA and provide intensive symptomatic treatment and monitoring.
- **Tardive Dyskinesia (TD)**, a syndrome of potentially irreversible, dyskinetic, and involuntary movements which may increase as the duration of treatment and total cumulative dose increases. The syndrome can develop after a relatively brief treatment period, even at low doses, or after treatment discontinuation. Given these considerations, CAPLYTA should be prescribed in a manner most likely to reduce the risk of TD. Discontinue CAPLYTA if clinically appropriate.
- **Metabolic Changes**, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with antipsychotics. Measure weight and assess fasting plasma glucose and lipids when initiating CAPLYTA and monitor periodically during long-term treatment.
- **Leukopenia, Neutropenia, and Agranulocytosis (including fatal cases)**. Perform complete blood counts in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Discontinue CAPLYTA if clinically significant decline in WBC occurs in absence of other causative factors.
- **Orthostatic Hypotension and Syncope**. Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension.
- **Falls**. CAPLYTA may cause somnolence, postural hypotension, and motor and/or sensory instability, which may lead to falls and, consequently, fractures and other injuries. Assess patients for risk when using CAPLYTA.
- **Seizures**. Use CAPLYTA cautiously in patients with a history of seizures or with conditions that lower seizure threshold.
- **Potential for Cognitive and Motor Impairment**. Advise patients to use caution when operating machinery or motor vehicles until they know how CAPLYTA affects them.
- **Body Temperature Dysregulation**. Use CAPLYTA with caution in patients who may experience conditions that may increase core body temperature such as strenuous exercise, extreme heat, dehydration, or concomitant anticholinergics.
- **Dysphagia**. Use CAPLYTA with caution in patients at risk for aspiration.

Drug Interactions: Avoid concomitant use with CYP3A4 inducers. Reduce dose for concomitant use with strong CYP3A4 inhibitors (10.5 mg) or moderate CYP3A4 inhibitors (21 mg).

Special Populations: Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Reduce dose for patients with moderate or severe hepatic impairment (21 mg).

Adverse Reactions: The most common adverse reactions in clinical trials with CAPLYTA vs placebo were:

- Schizophrenia: somnolence/sedation (24% vs 10%) and dry mouth (6% vs 2%).
- Bipolar Depression (Monotherapy, Adjunctive therapy): somnolence/sedation (13% vs 3%, 13% vs 3%), dizziness (8% vs 4%, 11% vs 2%), nausea (8% vs 3%, 9% vs 4%), and dry mouth (5% vs 1%, 5% vs 1%).

CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules.

Please see accompanying full Prescribing Information, including Boxed Warnings.